RENALYTIX AI PLC LS-,0025
RENALYTIX AI PLC LS-,0025
Share · GB00BYWL4Y04 · A2N765 (XLON)
Overview Financial Indicators
0,07 GBP
0,55 % 0,0004 GBP
Closing Price XLON 09.06.2025: 7,29 GBX
London (XLON) · Current prices and charts at MoneyPeak
09.06.2025 11:54

Current Prices from RENALYTIX AI PLC LS-,0025

ExchangeTickerCurrencyLast TradePriceDaily Change
XLON: London
London
RENX.L
GBX
09.06.2025 11:54
7,29 GBX
7,25 GBX
+0,55 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
0,55 % 0,55 % -8,99 % -20,76 % -8,30 % -55,82 % -98,36 %

Company Profile for RENALYTIX AI PLC LS-,0025 Share

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.

Invested Funds

The following funds have invested in: RENALYTIX AI PLC LS-,0025 invested:

Fund
iShares MSCI UK Small Cap UCITS ETF GBP (Acc)
Vol. in million
593,21
Percentage (%)
0,10 %

Company Data

Name RENALYTIX AI PLC LS-,0025
Company Renalytix Plc
Website https://renalytix.com
Primary Exchange XLON London
WKN A2N765
ISIN GB00BYWL4Y04
Asset Class Share
Sector Healthcare
Industry Medical - Healthcare Information Services
CEO Mr. James R. McCullough M.B.A.
Market Capitalization 26 Mio
Country United States of America
Currency GBP
Employees 0,1 T
Address 1460 Broadway, 10036 New York
IPO Date 2018-11-06

Ticker Symbols

Name Symbol
Frankfurt 2O9.F
London RENX.L

More Shares

Investors who RENALYTIX AI PLC LS-,0025 hold also have the following shares in their portfolio:
BFCM 21/28 MTN
BFCM 21/28 MTN Bond
KRED.F.WIED.23/31 MTN
KRED.F.WIED.23/31 MTN Bond
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025